Search

Your search keyword '"Kruijsen, Marijn W.M."' showing total 3 results
Start Over Author "Kruijsen, Marijn W.M."
3 results on '"Kruijsen, Marijn W.M."'

1. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial

Author

Jeurissen, Maurice E.C., Boerbooms, Agnes M. Th., Van de Putte, Levinus B.A., Doesburg, Wim H., Mulder, Jan, Rasker, Johannes, J., Kruijsen, Marijn W.M., Haverman, Joost F., Van Beusekom, Henk J., Muller, Wim Hissink, Franssen, Marcel J.A.M., and De Rooy, Dirk-Jan R.A.M.

Subjects
Methotrexate -- Evaluation, Rheumatoid arthritis -- Drug therapy, Azathioprine -- Evaluation, Health
Abstract

Rheumatic diseases such as rheumatoid arthritis (RA) have an autoimmune basis, in which the body inappropriately makes antibodies that recognize and attack the body's own tissues. The efficacy and toxicity of two drugs, azathioprine (AZA) and methotrexate (MTX), were compared in 64 patients (43 female) with RA who were unresponsive or had suffered side effects from gold therapy or d-penicillamine. Of the 33 subjects taking AZA, 13 discontinued due to severe side effects, chiefly severe vomiting. MTX side effects were primarily consisted of elevated blood levels of liver enzymes (suggestive of liver dysfunction), mouth ulcers, nausea, and vomiting. Of the 50 patients (20 receiving AZA and 30 receiving MTX) who completed 24 weeks of drug therapy, patients using MTX improved significantly compared with baseline status, medical symptoms, and laboratory results. This improvement extended to 48 weeks of therapy. Assessments at monthly intervals up to 24 weeks showed significantly greater improvement with time in the number of swollen joints, level of pain, and laboratory tests indicating severity of inflammatory disease. Seventy-six percent of MTX patients and 50 percent of AZA patients had a significant improvement in the disease activity score after 48 weeks, but MTX patients responded more rapidly. Overall, the study indicates that, for treating RA, MTX is more effective and produces fewer severe side effects than AZA. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

2. Parenteral gold preparations. Efficacy and safety of therapy after switching from aurothioglucose to aurothiomalate

Author

Van Roon, Eric N., Van De Laar, Mart A.F.J., Janssen, Matthijs, Kruijsen, Marijn W.M., Jansen, Tim L.T.A., Brouwers, Jacobus R.B.J., PharmacoTherapy, -Epidemiology and -Economics, and Groningen University Institute for Drug Exploration (GUIDE)

Subjects
SODIUM AUROTHIOMALATE, DRUGS, CHRYSOTHERAPY, RANDOMIZED CONTROLLED-TRIAL, INTRAMUSCULAR GOLD, RHEUMATOID-ARTHRITIS, HYDROXYCHLOROQUINE, METHOTREXATE, AURANOFIN, THIOMALATE
Abstract

Objective. For reasons of insufficient quality of the raw material, aurothioglucose was withdrawn from the Dutch market at the end of 2001. Aurothiomalate became available as an alternative preparation. We followed a cohort of patients during the first year after switching from aurothioglucose to aurothiomalate to study efficacy and tolerability. Methods. Patients were observed at baseline and at 3 and 12 months after switching. At each visit, data on adverse drug reactions (ADR), withdrawal, and disease activity were collected. Results. In total 120 patients were included [age 63 (SD 15) yrs, 68% female, 93% with rheumatoid arthritis, duration of disease 15 (SD 9) years, 82% I-M rheumatoid factor-positive, with 9 (SD 9, range 0.1-45) yrs of previous aurothioglucose therapy]. Nineteen patients (16%) reported an ADR taking aurothiomalate not previously experienced with aurothioglucose, the most frequently reported being pruritus, dermatitis/stomatitis, and chrysiasis/hyperpigmentation. Twenty-nine patients (24%) withdrew from aurothiomalate within 12 months of followup for reasons of inefficacy (14%), ADR (7%), or disease in state of remission (3%). Kaplan-Meier estimates show aurothiomalate survival rates of 78.5% after 12 months. No statistically significant differences between the disease activity indicators during followup visits compared with the baseline visit were detected for the patients continuing aurothiomalate. Conclusion. Within the first 12 months after switching from aurothioglucose, 24% of patients withdrew from aurothiomalate. Sixteen percent of patients reported novel ADR. For the population continuing to take aurothiomalate no clinically relevant changes in disease activity were recorded after switching.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results